Key Points
- Glaukos CFO Alex Thurman sold 10,000 shares on July 9 at an average price of $155, totaling about $1.55 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and his direct holdings fell 18.63% to 43,681 shares.
- The stock has been trading near its 52-week high, opening at $152.76 and recently touching $156.60. Glaukos has a market cap of about $8.97 billion and remains heavily owned by institutions, which hold 99.04% of shares.
- Recent financial results showed strong revenue growth: the company beat earnings and revenue estimates in its latest quarter, with revenue up 41.2% year over year to $150.57 million. Analysts currently rate the stock a Moderate Buy with an average price target of $151.77.
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 10,000 shares of the company's stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $155.00, for a total transaction of $1,550,000.00. Following the completion of the sale, the chief financial officer directly owned 43,681 shares of the company's stock, valued at approximately $6,770,555. This trade represents a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Glaukos Stock Up 0.0%
Shares of Glaukos stock opened at $152.76 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $156.60. The firm's 50-day moving average is $132.67 and its two-hundred day moving average is $120.98. The stock has a market cap of $8.97 billion, a price-to-earnings ratio of -46.57 and a beta of 0.75.
Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter last year, the firm posted ($0.22) EPS. The company's revenue for the quarter was up 41.2% on a year-over-year basis. As a group, research analysts expect that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Glaukos
Hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Alliance LLC grew its holdings in Glaukos by 4.5% in the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier's stock worth $247,000 after purchasing an additional 98 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier's stock valued at $158,000 after purchasing an additional 122 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 132 shares during the last quarter. CWM LLC boosted its position in shares of Glaukos by 25.2% in the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock worth $80,000 after purchasing an additional 143 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in shares of Glaukos by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier's stock worth $947,000 after purchasing an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently issued reports on GKOS shares. Stifel Nicolaus set a $170.00 target price on Glaukos in a report on Thursday, April 30th. Wall Street Zen upgraded Glaukos from a "hold" rating to a "buy" rating in a report on Saturday, July 4th. William Blair reissued an "outperform" rating on shares of Glaukos in a research report on Tuesday, May 26th. Wells Fargo & Company upped their price objective on Glaukos from $135.00 to $138.00 and gave the stock an "overweight" rating in a research note on Thursday, April 30th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $165.00 price objective on shares of Glaukos in a research report on Wednesday, July 1st. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $151.77.
Get Our Latest Analysis on GKOS
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
